ClinicalTrials.gg
CompletedNCT00837330Updated Apr 16, 2019Results posted

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

A Phase 1/2 interventional study of ranibizumab 0.5 or 0.3 mg/0.05 cc in Polypoidal Choroidal Vasculopathy, sponsored by Southeast Retina Center, Georgia. Completed at 1 site in United States. Open to participants aged 35 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Southeast Retina Center, Georgia · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Polypoidal Choroidal Vasculopathy · United States.

Enrollment
3rd of 12
20 · median 20
Started
2006
the only one that year
Phase 1/2
5 of 13
none open now
Registered
3rd of 13
by date
Lead sponsor
3 of 13
Southeast Retina Center, Georgia

Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2006, is one of 5 in phase 1/2, and was the 3rd registered.

Polypoidal Choroidal Vasculopathy

55 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 7 are open to participants now.

Browse Polypoidal Choroidal Vasculopathy studies →

Open to participants now

1 of the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Polypoidal Choroidal Vasculopathy studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 35 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, or all of them as a file.
02

Study summary

This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of tiny, abnormal blood vessels under the retina. These abnormal blood vessels can bleed or leak fluid, causing disruption of normal retinal function and vision loss. Ranibizumab is a drug that is FDA-approved for the treatment of wet age-related macular degeneration (AMD) and is injected directly into the eye. Given the efficacy of ranibizumab in the treatment of wet AMD, and the postulated similarity between the disease mechanisms involved in both wet AMD and PCV, we believe ranibizumab will have a beneficial effect on visual function in patients with PCV.

Read the detailed description

Please see above description. Phase I/II safety study; prospective, open-label, single-center, non-randomized, uncontrolled, consecutive interventional case series. Enrolled patients are >35 years old and display exudative, active polypoidal choroidal vasculopathy (PCV) in 1 eye. PCV is defined as choroidal neovascularization that displays occult characteristics on fluorescein angiography and polypoidal interconnecting vascular channels with saccular dilatations on indocyanine green angiography and/or fluorescein angiography. Eyes receive 3 consecutive, monthly intravitreal ranibizumab injections (0.5 mg or 0.3 mg/0.05 cc) followed by monthly evaluations with the option of additional intravitreal ranibizumab or alternative treatments at the discretion of the investigator. Baseline and follow-up evaluations include medical history, blood pressure, physical examination, early treatment diabetic rentinopathy study (ETDRS) best-corrected visual acuity (BCVA), intraocular pressure measurement, complete ophthalmologic examination, fundus photography, fluorescein/ indocyanine green (ICG) angiography, and optical coherence tomography (OCT).

03

Conditions studied

  • Polypoidal Choroidal Vasculopathy

Keywords

  • polypoidal choroidal vasculopathy
  • choroidal neovascularization
  • ranibizumab
  • Lucentis
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >35 years
  • Exudative, active PCV in 1 eye.
  • PCV is defined as choroidal neovascularization that displays occult characteristics on fluorescein angiography and polypoidal interconnecting vascular channels with saccular dilatations on indocyanine green angiography and/or fluorescein angiography.

Exclusion criteria

Exclusion Criteria:

  • Age \<35 years
  • Prior treatment with non-ranibizumab therapies (e.g., laser, surgery, or bevacizumab)
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5 mg/ 0.05 cc

    Intraocular injection of 0.5 mg/ 0.05 cc ranibizumab

    Drug: ranibizumab 0.5 or 0.3 mg/0.05 cc

  • Experimental
    Ranibizumab 0.3 mg/ 0.05 cc

    Intraocular injection of 0.3 mg/ 0.05 cc ranibizumab

    Drug: ranibizumab 0.5 or 0.3 mg/0.05 cc

Interventions

  • Drugranibizumab 0.5 or 0.3 mg/0.05 cc

    Drug page: RanibizumabStudies of RanibizumabRanibizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Commonly Reported and Notable Adverse Events

    Incidence and severity of ocular adverse events, as identified by indirect and direct examination. Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more of clinical macula (arcade to arcade), disease-related vitreous hemorrhage, injection-related endopthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.

    Time frame: 2 years

07

Results

Posted Jun 23, 2014

Participant flow

Twenty subjects from one site in the United States will be enrolled. Subjects with active, exudative-PCV who have provided informed consent will be eligible. Date of first subject enrolled: May 19, 2006. Date of last subject enrolled: October 8, 2008.

Participant flow — Overall Study
MilestoneIntraocular Injection 0.5 mg RanibizumabIntraocular Injection 0.3 mg Ranibizumab
Started1010
Completed97
Not completed13
Withdrew: Lost to follow-up13

Outcome measures

PrimaryCommonly Reported and Notable Adverse Events

Incidence and severity of ocular adverse events, as identified by indirect and direct examination. Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more of clinical macula (arcade to arcade), disease-related vitreous hemorrhage, injection-related endopthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.

Time frame:
2 years
Reported as:
Number · participants
Commonly Reported and Notable Adverse Events
participantsRanibizumab 0.5 mgRanibizumab 0.3 mg
Spider webs12
Eye pain, burning23
Wavy Lines12
Seeing Dark spots22
Flashes of Light11
Floaters41
Worsening visual acuity21
Eye irritation12
Mild Vitreous Hemorrhage12
Blurry vision23
Eyelid swelling21
Transient increased blood pressure02
Injection-related pain23
Injection-related eyelid swelling21
Macular hole01
Transient increased intraocular pressure01
Chalazion10
Stye20
Decreased color vision01
Foreign Body Sensation10
Posterior Vitreous detachment01
Retinal Pigment epithelial changes01
Worsened Night Vision10
Worsened polypoidal choroidal vasculopathy10
Worsening of Cataracts12
Itchy, watery eyes12

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg—0/10 (0%)9/10 (90%)
Ranibizumab 0.3 mg—0/10 (0%)8/10 (80%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventRanibizumab 0.5 mgRanibizumab 0.3 mg
FloatersEye disorders4/101/10
Injection Site PainEye disorders2/103/10
Ocular BlurrinessEye disorders2/103/10
Worsening of CataractEye disorders1/102/10
Itchy, Watery EyesEye disorders1/102/10
Vitreous HemorrhageEye disorders1/102/10
Seeing Dark SpotsEye disorders2/102/10
Worsened Visual AcuityEye disorders2/101/10
Eyelid SwellingEye disorders2/101/10
StyeEye disorders2/100/10

Baseline characteristics

10 subjects were enrolled into each of the two ranibizumab groups (0.3 mg/ 0.5 mg)

Age, Categorical
Age, Categorical(Participants)Ranibizumab 0.5 mg/ 0.05 ccRanibizumab 0.3 mg/ 0.05 ccTotal
<=18 years000
Between 18 and 65 years4711
>=65 years639
Age, Continuous
Age, Continuous(years)Ranibizumab 0.5 mg/ 0.05 ccRanibizumab 0.3 mg/ 0.05 ccTotal
Mean64 ± 1465 ± 864 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.5 mg/ 0.05 ccRanibizumab 0.3 mg/ 0.05 ccTotal
Female5712
Male538
Region of Enrollment
Region of Enrollment(participants)Ranibizumab 0.5 mg/ 0.05 ccRanibizumab 0.3 mg/ 0.05 ccTotal
United States101020
08

Study locations

1 site
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
09

References and documents

Publications

  • Marcus DM, Singh H, Lott MN, Singh J, Marcus MD. Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients. Retina. 2013 Jan;33(1):35-47. doi: 10.1097/IAE.0b013e3182618be0. PubMed 22990319 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2009
First posted
Feb 5, 2009
Start
May 2006
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Jun 23, 2014
Last update
Apr 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00837330
Lead sponsor
Southeast Retina Center, Georgia
Collaborators
Genentech, Inc.
Responsible party
Dennis M. Marcus, M.D. (Dr. Dennis M. Marcus Principal Investigator, Southeast Retina Center, Georgia) — Principal investigator
First posted
Feb 5, 2009
Start date
May 2006
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Jun 23, 2014
Last update
Apr 16, 2019

Study contacts

Dennis M. Marcus, M.D.
principal investigator · Southeast Retina Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion